Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.70 |
| ▸ | HTR6 known ✓ | P50406 | 5/20 | 0.60 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.50 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.70 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.70 |
| ▸ | F2 | P00734 | 2/20 | 0.62 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenethylamine SCHEMBL77780 | 0.98 | HTR2A (0.73) | HTR2ACYP2A6SMN1; SMN2TAAR1LOXL2 | |
| Phenethylamine SCHEMBL3721983 | 0.89 | HTR2A (0.67) | HTR2ACYP2A6SMN1; SMN2TAAR1LOXL2 | |
| Phenethylamine SCHEMBL245154 | 0.86 | HTR2A (0.94) | HTR2ACYP2A6SMN1; SMN2TAAR1LOXL2 | |
| Phenethylamine SCHEMBL27616397 | 0.84 | HTR2A (0.73) | HTR2ACYP2A6SMN1; SMN2TAAR1LOXL2 | |
| Phenethylamine SCHEMBL11319344 | 0.84 | HTR2A (0.73) | HTR2ACYP2A6SMN1; SMN2TAAR1LOXL2 | |
| Phenethylamine SCHEMBL2034484 | 0.84 | HTR2A (0.80) | HTR2ACYP2A6SMN1; SMN2TAAR1LOXL2 | |
| Phenethylamine SCHEMBL16294846 | 0.84 | HTR2A (0.89) | HTR2ACYP2A6SMN1; SMN2TAAR1LOXL2 | |
| Phenethylamine SCHEMBL29277512 | 0.84 | HTR2A (0.89) | HTR2ACYP2A6SMN1; SMN2TAAR1LOXL2 | |
| Phenethylamine SCHEMBL11664723 | 0.84 | HTR2A (0.89) | HTR2ACYP2A6SMN1; SMN2TAAR1LOXL2 | |
| Phenethylamine SCHEMBL1332244 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230383367-A1 | METHOD AND KIT FOR SIMULTANEOUSLY DETECTING A PLURALITY OF DIFFERENT PATHOGENS IN A SAMPLE | Xebios Diagnostics Group GmbH (DE) | 2023-11-30 | — | — | US | claimed |
| CN-107771285-A | Method | 阿奎尔诊断有限公司 | 2018-03-06 | — | — | CN | claimed |
| WO-2011014051-A1 | A METHOD FOR CONTROLLING PROTEOLYTIC DEGRADATION OF RECOMBINANT PROTEINS | UNIVERSITI PUTRA MALAYSIA (MY) | 2011-02-03 | — | — | WO | claimed |
| EP-1750743-A4 | ORAL FORMULATIONS COMPRISING BONE MORPHOGENETIC PROTEINS FOR TREATING METABOLIC BONE DISEASES | GLAXOSMITHKLINE ZAGREB (HR) | 2009-07-08 | — | — | EP | claimed |
| US-20070265187-A1 | Oral Formulations Comprising Bone Morphogenetic Proteins For Treating Metabolic Bone Diseases | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. ZA ISTRAZIVANJE I RAZVOJ (HR) | 2007-11-15 | — | — | US | claimed |
| EP-1750743-A2 | ORAL FORMULATIONS COMPRISING BONE MORPHOGENETIC PROTEINS FOR TREATING METABOLIC BONE DISEASES | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-02-14 | — | — | EP | claimed |
| WO-2005110465-A2 | ORAL FORMULATIONS COMPRISING BONE MORPHOGENETIC PROTEINS FOR TREATING METABOLIC BONE DISEASES | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2005-11-24 | — | — | WO | claimed |
| US-6913932-B2 | Formaldehyde-ammonium salt complexes for the stabilization of blood cells | BECKMAN COULTER, INC. (US) | 2005-07-05 | — | — | US | claimed |
| US-6235509-B1 | ADDING THESE COMPOUNDS TO SAMPLE AVOIDS NONSPECIFIC DERIVATIZATION OF PROTEINS OTHER THAN SERINE PROTEASES; USED IN PROCESS FERMENTATIONS, CULTURE BROTHS AND CELL LYSATES | ROCHE DIAGNOSTICS GMBH (DE) | 2001-05-22 | — | — | US | claimed |
| US-12460016-B2 | Plasma kallikrein binding proteins | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-04 | — | — | US | disclosed |
| US-20240317826-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR IDENTIFYING AN AGENT FOR TREATING HIV-1 INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-26 | — | — | US | disclosed |
| US-20230383367-A1 | METHOD AND KIT FOR SIMULTANEOUSLY DETECTING A PLURALITY OF DIFFERENT PATHOGENS IN A SAMPLE | Xebios Diagnostics Group GmbH (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230340150-A1 | PLASMA KALLIKREIN BINDING PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230112931-A1 | PLASMA KALLIKREIN BINDING PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-13 | — | — | US | disclosed |
| US-20050175601-A1 | Use of LIMK-1, its analogues and ligands for the production of a medicament against a thrombus formation or blood clotting disease | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005053734-A1 | USE OF LIMK-1, ITS ANALOGUES AND LIGANDS FOR THE PRODUCTION OF A MEDICAMENT AGAINST A THROMBUS FORMATION OR BLOOD CLOTTING DISEASE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-06-16 | — | — | WO | disclosed |
| EP-1541169-A1 | Use of limk-1, its analogues and ligands for the production of a medicament against a thrombus formation of blood clotting disease | Aventis Pharma Deutschland GmbH (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040229250-A1 | Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies | TRANSKARYOTIC THERAPIES, INC. (US) | 2004-11-18 | — | — | US | disclosed |
| WO-2004072275-A2 | DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER USING A FORMYLGLYCINE GENERATING ENZYME (FGE) | TRANSKARYOTIC THERAPIES, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2001077160-A1 | A MODIFIED H-NS PEPTIDE OF SALMONELLA TYPHIMURIUM, CAPABLE OF MODULATING THE OLIGOMERIZATION OF H-NS | UNIVERSITY COLLEGE LONDON (GB) | 2001-10-18 | — | — | WO | disclosed |